Mabwell Bioscience-B
02493 · HKEXInnovative biotech focused on oncology & age-related diseases; core Nectin-4 ADC 9MW2821 in pivotal Phase III; 4 biosimilars launched
IPO Timeline
- OpenApr 20
- CloseApr 23
- AllotmentApr 27
- PaymentApr 28
- ListingApr 28
Key Facts
Issue Price
HKD 27.64
Min Entry Fee
HKD 6,203.93
Shares Issued
47.13M
Lot Size
200
Total Raise
HKD 1302.7M
Estimated Market Cap
—
Public Allocation
10.0%
International Placement
90.0%
Business Overview
Innovative biotech focused on oncology & age-related diseases; core Nectin-4 ADC 9MW2821 in pivotal Phase III; 4 biosimilars launched
Use of Proceeds
1) 56.8% for clinical development of 9MW2821 for multiple indications across phases;
2) 17.7% for R&D of other pipeline assets in oncology & age-related diseases with high clinical need;
3) 15.5% for commercialization;
4) 10.0% for working capital and general corporate purposes
Sponsor Track Record
Intermediaries & Documents
Sponsors
- 中信證券(香港)有限公司
- 海通國際資本有限公司
Underwriters
- 中信里昂證券有限公司
- 海通國際證券有限公司
- 興證國際融資有限公司
- 招銀國際融資有限公司
- 建銀國際金融有限公司
Prospectus PDF
Prospectus PDF →Cornerstone Investors
- Junshi Hong Kong Limited
- Sanjin International Co., Ltd.
- Guohui (Hong Kong) Holdings Co., Limited
- Changrong International Co., Limited
- WuXi Biologics HealthCare Venture Limited
- Jin Xiu Zhong He (Beijing) Capital Management Co., Ltd.
Total
0
30.2% of placement
BBX does not participate in the allocation process for any IPO listed on this page. This page is for informational purposes only and is not investment advice.